RecruitingPrimary Sclerosing CholangitisPrimary Biliary CirrhosisCholangiocarcinoma
Biobank for Cholestatic Liver Diseases.
Eligible age
18–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Sponsor: Mayo Clinic
You may qualify if…
- ✓ PSC
- ✓ Patients diagnosed with PSC and who are between the age of 18 and 85 at time of enrollment in the study.
- ✓ The diagnosis of PSC will be based on standard PSC criteria including clinical and biochemical evidence of chronic cholestasis of at least six months duration, positive cholangiographic findings, and compatible liver biopsies if available.
- ✓ Patients with PSC who have undergone orthotopic liver transplantation will be offered enrollment except for collection of bile - please see below under Exclusion Criteria.
- ✓ Women with PSC of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation.
- ✓ PBC
- ✓ Patients diagnosed with PBC and who are between the age of 18 and 85 at time of enrollment in the study.
- ✓ The diagnosis of PBC will be based on standard PBC criteria including clinical and biochemical evidence of chronic cholestasis of at least six month duration, positive anti-mitochondrial antibodies in serum and compatible liver biopsies, if available.
You may not qualify if…
- ✕ PBC or PSC patients with known and overlapping other chronic liver diseases
- ✕ Patients unable to provide informed consent
- ✕ Prisoners and institutionalized individuals
- ✕ PSC with orthotopic liver transplantation
- ✕ History of Roux en Y
Where it's recruiting
Minnesota
Rochester
Source: ClinicalTrials.gov · NCT03445585 · last updated 2026-02-17